Background -Cystic fibrosis is usually diagnosed in childhood, but a number of patients are not diagnosed until adulthood. The aim of this study was to investigate whether patients diagnosed at an older age had a different genetic constitution, manifestations of disease, and prognosis from those diagnosed at an early age. Methods -Clinical data and results oflung function tests and DNA analysis of 143 adult patients with cystic fibrosis were entered into a computerised database. Patients diagnosed before their 16th birthday (early diagnosis, ED) were compared with those diagnosed at 16 years of age or older (late diagnosis, LD). Results -Mean age of diagnosis of the ED group was 4-6 years compared with 27-7 years for the LD group. Mean (SD) percentage predicted pulmonary function was better for the LD group than for the ED group: forced expiratory volume in one second (FEVy) 72-5 (31.1)% and 52-0 (24*8)%, and forced vital capacity (FVC) 89-8 (25-7)% and 71 9 (23-0)%, respectively.
Colonisation with Pseudomonas aeruginosa was present in 70% ofthe ED group and 24% of the LD group. In the ED group 81% had pancreatic insufficiency compared with only 12% ofthe LD group. None ofthe LD group was homozygous for AF508 compared with 58% of the ED group. In the LD group 72% were compound AF508 heterozygotes and 28% had two non-AF508 mutations. Pancreatic insufficiency was considered to be present when patients had a faecal fat excretion of >10% fat intake during three day fat balance studies, or when gross steatorrhoea necessitated the use of pancreatic enzyme supplements, and diabetes mellitus (DM) was considered to be present when insulin was needed to control a patient's blood glucose concentration.
DNA was analysed for the following mutations: E60X, R117H, A455E, AI507, AF508, G542X, S549N, G550X, G551D, R553X, R560T, R1162X, S1251N, W1282X, N1303K, 621 + 1G-+T, 1717-1G--+A. These In the ED group 47% presented with recurrent respiratory tract infections, 45% with abnormal stools and other gastrointestinal tract symptoms, 5% with meconium ileus, 2-5% with rectal prolapse, 14% with poor growth or weight gain, and 6% with ENT symptoms such as nasal polyps or recurrent sinusitis. In 14% diagnosis was made because of a sibling or family member with cystic fibrosis (because many patients had more than one presenting symptom, the total exceeds 100%). In the LD group the presenting signs were recurrent respiratory tract infections in 92%, gastrointestinal tract complaints in 8%, one patient (4%) presented with male infertility, and one patient (4%) with oesophageal varices. In 24% the diagnosis was made because of cystic fibrosis in a sibling.
DNA of all patients was analysed for CFTR mutations. In the ED group the AF508 mutation was found on 74-2% of all cystic fibrosis chromosomes tested. Sixty eight patients (47%) were homozygous for the AF508 mutation (table 2). In the LD group the frequency ofthe AF508 mutation was 36-0%, and none of the patients was homozygous for this mutation (table 2) . The difference between the two groups is highly significant (p<0-0001). Genetic and clinical features ofpatients with late diagnosis of cystic fibrosis Age at diagnosis (years)
Cumulative percentages ofpatients with cystic fibrosis diagnosed by age and by the presence of AF508 mutation. The influence of the presence of the AF508 mutation on the age of diagnosis is shown in the figure. All AF508 homozygotes were diagnosed by age 13, whereas 39% of patients not bearing the AF508 mutation were diagnosed at an age older than 16 years. The frequency ofall CFTR mutations found is listed in table 3. The A455E mutation was relatively frequent in the LD group. In the ED group 13-2% of mutations could not be identified compared with 26&0% in the LD group. Table 4 lists the results of lung function tests for the two groups. In the ED group FEV1 and FVC were significantly lower than in the LD group, despite the average higher age of the latter group. In both groups of patients the decline in FEV, was faster than in the general population. However, the average annual decline in FEV1 was more than twice as large in ED patients than in LD patients. In the ED group a decline of FEV1 to 30% is predicted by 38-3 years and for the LD group at 94 9 years. When the FEV1 falls below 30% the likelihood of death within two years is increased and serious disability can be anticipated. '7 In the ED group colonisation with Pseudomonas aeruginosa was present in 83 patients (70 3%) compared with six patients (24%) in the LD group (p<0005).
There was one active smoker in the ED group, and one active and seven former smokers in the LD group.
Non-pulmonary disease symptoms are summarised in table 5. Pancreatic insufficiency was present in 96 patients (81 %) of the ED group compared with only three (12%) in the LD group (p<0 005). Diabetes mellitus occurred in 17 patients (14%) in the ED group and in two (8%) of the LD group (NS). All ED patients with diabetes had an exocrine pancreatic insufficiency. In the LD group one of the patients with diabetes had an exocrine pancreatic insufficiency while in the other patient diabetes was associated with the use of oral corticosteroids.
Discussion
This study describes the clinical and genetic features of patients in whom cystic fibrosis was diagnosed late compared with those in whom it was diagnosed early. Late diagnosis appears to be not just a case of doctor or patient delay, but to constitute a separate patient group with a distinct genetic constitution and often milder pulmonary and non-pulmonary disease symptoms.
In earlier descriptions of groups of adult patients with cystic fibrosis 3 5-21 % were diagnosed at 16 years or older.818 22 In these reports on adult patients late diagnosis was not associated with milder disease. In fact, it was found that patients diagnosed at an early age generally did better than those diagnosed at a later age2324 or there was no difference.'922 However, our study shows that late diagnosis does not necessarily have to be detrimental to prognosis.
There are a number of reasons for late diagnosis. Firstly, mild or absent symptoms may delay a patient seeking medical attention. Secondly, a physician may not recognise cystic fibrosis, especially when the presenting symptoms are atypical. Finally, there may be problems in the diagnosis of cystic fibrosis as, for example, when there are repeated normal or borderline sweat tests.2526
Most ofthose diagnosed early presented with a combination of gastrointestinal and pul-monary symptoms, while in the late diagnosis group most were diagnosed because of recurrent pulmonary infections or because cystic fibrosis was found in a sibling. Gastrointestinal symptoms rarely led to the diagnosis of cystic fibrosis in this group. Until now the cystic fibrosis genotype was not predictive for pulmonary function or for prognosis.27 Our results make it much more likely that there is a link between CFTR mutations and the severity of pulmonary disease. Among our patients all AF508 homozygotes were in the early diagnosis group who had more severe pulmonary and non-pulmonary disease. Most of those diagnosed at 16 years or older were pancreatic sufficient, which is closely related to the type of CFTR mutation.2829 The A455E mutation was frequently found among this group of patients and preliminary studies indicate that this mutation, known to be related to pancreatic sufficiency,29 may be associated with mild pulmonary disease.30 It seems that other CFTR mutations (some of which are still unidentified) in patients diagnosed late are associated with pancreatic sufficiency and also with mild pulmonary disease. It is doubtful that pancreatic and pulmonary status are determined entirely by independent genetic factors. 
